Last updated: July 31, 2026
ESKALITH is the legacy brand name for lithium carbonate, an established mood stabilizer used primarily in bipolar disorder. The branded product has no material active development program, no meaningful branded clinical-trial pipeline, and no identifiable active patent barrier affecting generic lithium carbonate. Commercial demand continues through generic lithium carbonate tablets, capsules, and extended-release products rather than through ESKALITH-branded sales.
What is the current clinical-trial status of ESKALITH?
No active late-stage clinical program is associated with ESKALITH as a branded product. Current lithium studies generally evaluate lithium carbonate or lithium treatment as a class, not the ESKALITH brand.
ClinicalTrials.gov includes studies involving lithium in areas such as:
- Bipolar disorder and suicide prevention
- Maintenance treatment and relapse prevention
- Treatment-resistant depression
- Neurodegenerative diseases
- Amyotrophic lateral sclerosis
- Alzheimer’s disease and cognitive decline
- Cluster headache and other neurologic conditions
- Lithium monitoring, dosing, and pharmacogenomics
These studies do not create a new ESKALITH regulatory or commercial franchise. A trial involving generic lithium carbonate would not ordinarily expand the label of the discontinued or low-visibility branded product unless the sponsor controls a specific formulation, indication, or regulatory application.
What clinical evidence supports lithium carbonate?
Lithium has extensive historical evidence for acute mania, bipolar maintenance, and reduction of mood-episode recurrence. The evidence base is older than that of most current psychiatric medicines, but lithium remains clinically differentiated by its established role in long-term relapse prevention and its association with reduced suicide risk in some populations.
The principal limitations are its narrow therapeutic index and the need for laboratory monitoring. Serum lithium concentrations can change materially with renal impairment, dehydration, sodium depletion, and interactions with medicines such as nonsteroidal anti-inflammatory drugs, thiazide diuretics, and angiotensin-converting enzyme inhibitors.
What is the FDA regulatory status of ESKALITH?
Lithium carbonate is FDA-approved for the treatment of manic episodes and for maintenance therapy in bipolar disorder. ESKALITH products were historically approved in immediate-release and controlled-release forms. Current U.S. prescribing is dominated by generic lithium carbonate products and other lithium carbonate extended-release products.
FDA labeling requires monitoring of:
- Serum lithium concentration
- Kidney function
- Thyroid function
- Electrolytes
- Hydration and sodium balance
- Pregnancy-related risks and neonatal exposure
Lithium is not a biologic. Biosimilar approval pathways do not apply. Any competitive entry would proceed through a generic drug application, an abbreviated new drug application, or, for a novel formulation, a full or supplemental NDA pathway.
When does ESKALITH lose exclusivity?
ESKALITH’s original product and formulation exclusivities expired decades ago. The active ingredient, lithium carbonate, is a longstanding generic compound. No meaningful branded exclusivity period remains for the legacy ESKALITH product.
What patents protect ESKALITH?
No currently material, enforceable patent estate is generally associated with the original ESKALITH active ingredient. Lithium carbonate is an old small-molecule compound, and the historical composition-of-matter protection has expired.
Potential patent protection in the lithium market would more likely relate to:
- Extended-release matrices
- Modified dissolution profiles
- Dosing regimens
- Combination products
- Digital adherence systems
- Renal or thyroid monitoring technology
- Novel lithium formulations designed to reduce toxicity or improve tolerability
Those patents would protect a specific product or method, not the ESKALITH name or generic lithium carbonate itself.
How many patents cover ESKALITH?
There is no commercially significant active patent estate covering conventional ESKALITH or standard generic lithium carbonate tablets. Legacy patents associated with branded controlled-release formulations are expired or no longer relevant to ordinary generic lithium carbonate products.
The principal barriers to market participation are manufacturing compliance, product quality, supply continuity, bioequivalence, and consistent extended-release performance. Patent litigation is not the principal risk for conventional lithium carbonate.
What is the Orange Book status of ESKALITH?
The Orange Book historically listed lithium carbonate products under various manufacturer and application records, including branded and generic products. The practical market status has changed because ESKALITH is no longer the central commercial product in the category.
Orange Book considerations include:
| Issue |
ESKALITH assessment |
| Active ingredient |
Lithium carbonate |
| Therapeutic category |
Antimanic agent |
| Dosage forms |
Immediate-release and extended-release tablets or capsules |
| Regulatory pathway |
Legacy NDA and current ANDA products |
| Active composition patent |
None of material commercial relevance |
| Active branded exclusivity |
None expected |
| Paragraph IV significance |
Low for the legacy brand |
| Generic availability |
Broad |
| Biosimilar exposure |
Not applicable |
Orange Book listings should be checked by product and application number because product availability and marketing status can change. A historical NDA listing does not establish that a branded product remains actively marketed.
Are there Paragraph IV challenges to ESKALITH?
Paragraph IV litigation is unlikely to be commercially significant for ESKALITH. Generic lithium carbonate products have been available for many years, and the core active ingredient is not protected by a live composition-of-matter patent.
A Paragraph IV filing could arise only if a current product had a listed patent covering a particular extended-release formulation, delivery mechanism, or method of use. Such a challenge would concern that specific patent, not the underlying lithium carbonate market.
What generic entry risks exist for ESKALITH?
The risk is substitution rather than future generic entry. Generic lithium carbonate already supplies the market.
Potential competitive events include:
- Additional manufacturers entering the immediate-release segment.
- New extended-release products receiving FDA approval.
- Hospital and pharmacy substitution toward lower-cost suppliers.
- Product discontinuations caused by manufacturing or raw-material constraints.
- Development of novel lithium formulations that compete on tolerability or monitoring burden.
For investors and licensors, the relevant question is not whether generic entry will occur. It is whether a supplier can maintain reliable production and obtain favorable reimbursement in a low-price market.
What formulations are protected in the lithium carbonate market?
Conventional immediate-release lithium carbonate has limited differentiation. Extended-release products can command greater regulatory and technical scrutiny because release characteristics affect exposure, tolerability, dosing frequency, and bioequivalence.
Immediate-release lithium carbonate
Immediate-release products are available as tablets and capsules. They are generally interchangeable within prescribing and pharmacy substitution rules when the dosage form and strength are appropriate, subject to clinician judgment and product labeling.
Extended-release lithium carbonate
Extended-release products are designed to reduce peak concentrations and support less frequent dosing. Their competitive value depends on:
- Release profile
- Bioequivalence
- Dose conversion requirements
- Tablet integrity
- Patient adherence
- Availability of multiple strengths
- Reimbursement and substitution rules
A formulation patent could have commercial value if it materially improves tolerability, adherence, or pharmacokinetic consistency. That value would not extend automatically to standard lithium carbonate products.
Novel lithium delivery systems
Research has explored lower-dose, targeted, implantable, and nanoparticle-based lithium delivery concepts. These approaches remain separate from the ESKALITH commercial product and would require new clinical, manufacturing, and regulatory validation.
How does ESKALITH compare with competing bipolar medicines?
ESKALITH competes commercially through generic lithium carbonate against both generic and branded mood stabilizers.
| Product class |
Examples |
Main competitive advantage |
Main limitation |
| Lithium salts |
Lithium carbonate, lithium citrate |
Long-term maintenance evidence; low generic cost |
Narrow therapeutic index; renal and thyroid monitoring |
| Anticonvulsant mood stabilizers |
Valproate, carbamazepine, lamotrigine |
Established use in bipolar-spectrum treatment |
Differing safety, reproductive, hepatic, or titration concerns |
| Atypical antipsychotics |
Quetiapine, lurasidone, cariprazine, olanzapine |
Acute bipolar depression or mania efficacy |
Metabolic, neurologic, and cost concerns |
| Long-acting injectables |
Aripiprazole and others |
Adherence support |
Administration burden and higher cost |
| Combination regimens |
Lithium plus antipsychotic or anticonvulsant |
Broader episode control |
Increased monitoring and adverse-event burden |
Lithium’s price advantage is substantial, but its monitoring requirements limit use in patients with renal disease, poor adherence, or difficulty accessing laboratory services.
What is the market size and revenue outlook for ESKALITH?
No reliable standalone revenue projection exists for ESKALITH as a brand because public market reports generally aggregate lithium carbonate with generic lithium products or broader mood-stabilizer categories.
The commercial outlook is best assessed in three layers:
| Market layer |
Outlook |
| ESKALITH-branded sales |
Minimal or immaterial relative to generic lithium |
| U.S. generic lithium carbonate |
Mature, price-sensitive, relatively stable demand |
| Global lithium therapeutic market |
Growth tied to bipolar diagnosis, treatment persistence, access to psychiatric care, and generic supply |
What will drive lithium carbonate demand?
Demand should remain linked to:
- Prevalence and diagnosis of bipolar disorder
- Continued use of lithium for maintenance therapy
- Clinical concern about suicide prevention
- Low generic pricing
- Treatment guidelines that retain lithium as a first-line or preferred option for selected patients
- Expansion of psychiatric care in emerging markets
Volume growth is likely to be modest rather than high-growth. Revenue growth is constrained by generic pricing, pharmacy substitution, and the absence of meaningful brand premium.
What could reduce market demand?
Risks include:
- Increased use of atypical antipsychotics and other mood stabilizers
- Clinician concerns about renal and thyroid toxicity
- Patient reluctance to undergo repeated serum monitoring
- Poor adherence caused by adverse effects
- Development of safer alternatives with comparable maintenance efficacy
- Supply interruptions or manufacturer withdrawals
What are the likely market scenarios through 2030?
| Scenario |
Market implication |
| Base case |
Stable to low-single-digit volume growth in generic lithium use; continued price pressure |
| Upside case |
Greater recognition of lithium’s maintenance and suicide-prevention value; increased treatment persistence |
| Downside case |
Substitution by newer agents, lower treatment initiation, or sustained supply disruption |
These scenarios apply to therapeutic lithium demand, not to ESKALITH-branded revenue. A return of ESKALITH as a large branded franchise would require a new owner, a differentiated formulation, or a new regulatory claim.
What patent litigation affects ESKALITH?
No major current patent litigation is generally associated with conventional ESKALITH or standard lithium carbonate products. Litigation risk is more likely to arise from:
- Product liability claims involving toxicity
- Manufacturing defects
- Labeling and warning disputes
- Competition over extended-release formulations
- ANDA disputes involving newer lithium products
- Distribution or supply agreements
The litigation profile is therefore different from that of recently launched branded medicines, where patent infringement cases commonly determine generic launch timing.
Are there licensing deals involving ESKALITH?
No current high-value licensing transaction is central to the ESKALITH market. The product’s commercial history includes legacy ownership and marketing arrangements, but those arrangements do not create a modern exclusivity platform.
A commercially relevant licensing opportunity would more likely involve:
- A proprietary extended-release lithium product
- A formulation intended to reduce peak-related adverse effects
- A monitoring or adherence platform
- A combination product
- A new indication supported by prospective clinical evidence
A license covering conventional lithium carbonate without formulation or clinical differentiation would have limited strategic value because multiple generic suppliers already compete in the category.
What manufacturing and intellectual-property barriers affect lithium carbonate?
Manufacturing barriers are more important than patent barriers.
Lithium products require tight control of:
- Active pharmaceutical ingredient purity
- Tablet content uniformity
- Dissolution and release characteristics
- Batch-to-batch potency
- Packaging and moisture protection
- Stability
- Supply-chain continuity
- Bioequivalence for modified-release products
Extended-release products carry greater technical risk than immediate-release products. A manufacturer can face regulatory action or product recalls if dissolution performance shifts or if tablet strength is inconsistent.
The market is also vulnerable to supplier concentration. Because lithium carbonate is inexpensive, manufacturers may exit if margins do not justify quality-system, compliance, and inventory costs.
What is the competitive landscape for lithium carbonate?
The competitive landscape is fragmented and generic. Competition occurs on price, contract reliability, wholesaler access, dosage-form breadth, and regulatory compliance.
The principal commercial groups include:
- U.S. generic manufacturers
- Global pharmaceutical suppliers
- Contract manufacturers
- Hospital and institutional suppliers
- Manufacturers of extended-release lithium carbonate
Brand identity has limited influence in routine pharmacy dispensing. Prescriber loyalty may persist for a particular extended-release product, but generic substitution and reimbursement policies usually control volume.
Key Takeaways
- ESKALITH is a legacy lithium carbonate brand with no material active development pipeline.
- Current lithium clinical research is conducted primarily under the generic active-ingredient name.
- Conventional lithium carbonate has no commercially meaningful active composition-of-matter patent protection.
- Generic substitution is already established; future generic entry is not the central commercial issue.
- FDA-regulated competition focuses on bioequivalence, extended-release performance, manufacturing quality, and supply reliability.
- ESKALITH-branded revenue is not a dependable standalone market category.
- Therapeutic lithium demand should remain broadly stable, with modest volume growth possible through 2030.
- The main commercial risks are generic pricing, monitoring burden, adverse effects, product supply, and substitution by newer bipolar medicines.
- Biosimilar risk does not apply because lithium carbonate is a small-molecule drug.
- A new lithium franchise would require formulation, delivery, monitoring, or clinical differentiation.
FAQs About ESKALITH
Is ESKALITH still available in the United States?
Generic lithium carbonate products are available, while the branded ESKALITH product has limited or uncertain current commercial availability. Pharmacy availability depends on manufacturer marketing status and wholesale supply.
Is ESKALITH the same as lithium carbonate?
Yes. ESKALITH is a historical brand name for lithium carbonate. Product-specific release characteristics and dosage instructions still matter when switching between immediate-release and extended-release products.
Can a patient switch from ESKALITH to generic lithium carbonate?
A switch should account for formulation, strength, release profile, serum concentration, and clinical response. Extended-release and immediate-release products are not interchangeable on a milligram-for-milligram basis without appropriate clinical management.
Does lithium carbonate have new clinical-trial potential?
Potential remains in maintenance treatment, suicide prevention, precision dosing, neuropsychiatric disease, and formulations designed to reduce toxicity. These opportunities concern lithium as an active ingredient, not the legacy ESKALITH brand.
What would make a new lithium product commercially valuable?
A product would need a defensible improvement in dosing convenience, renal or thyroid safety, tolerability, pharmacokinetic consistency, adherence, or clinical outcomes. Conventional lithium carbonate alone has limited differentiation and low pricing power.
References
- U.S. Food and Drug Administration. (n.d.). Lithium carbonate prescribing information and drug-label materials. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- National Library of Medicine. (n.d.). DailyMed: Lithium carbonate drug labels. https://dailymed.nlm.nih.gov
- National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov
- American Psychiatric Association. (2023). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association Publishing.
- National Institute for Health and Care Excellence. (2023). Bipolar disorder: Assessment and management. NICE guideline CG185. https://www.nice.org.uk/guidance/cg185
